Dianthus Therapeutics
DNTH
84.88
-0.52
-0.61%
Dianthus Therapeutics
US · DNTH
#2155 by market cap
Listed 1970
84.88
-0.52
-0.61%
Live - 5344 symbols - heartbeat 159s ago
· 2026-10-07 21:26
After-hours
84.88
0.00%
Overnight
85.24
+0.42%
- Market cap
- 4.75B
- P/E (TTM)i
- -20.02
- P/Bi
- 4.05
- EPSi
- -4.20
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on DNTH?
Anonymous reader poll. Unscientific, not investment advice.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
- Founded
- 2015
- CEO
- Mr. Marino Garcia
- Employees
- 92
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- dianthustx.com
Company profile
- Exchange
- US
- Symbol
- DNTH
- Market-cap rank
- #2155
- Listing date
- 1970-01-01
- Market cap
- 4.75B
- Float cap
- 4.74B
- Shares out
- 55.93M
- Float shares
- 55.81M
Sectors & themes
Quote time 2026-10-07 21:26:06 · For reference only, not investment advice and not tailored to your situation.